AI Summary
The text discusses the FDA approval of adjuvant abemaciclib in combination with endocrine therapy for high-risk hormone receptor positive early breast cancer based on the monarchE trial data. It also mentions data from the NATALEE trial on the efficacy of adjuvant ribociclib in the same population. The question raised is whether adjuvant ribociclib is ready for routine clinical practice and in which patients it should be used. The focus is on determining the readiness of incorporating ribociclib in clinical practice.
In 2021, data from the monarchE trial led to the FDA approval of adjuvant abemaciclib in combination with endocrine therapy (ET) for patients with high-risk hormone receptor positive (HR+) early breast cancer (EBC).1 Slamon et al recently published data from the NATALEE trial, which examined the efficacy of adjuvant ribociclib in HR+ EBC.2 These data leave us with the question: are we ready to incorporate ribociclib in routine clinical practice and if so, in whom?